AROA in the News

July 31, 2023
Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial...

Highlights are listed below. To read the full announcement, click here Financial Highlights Increased cash…

July 19, 2023
FY23 Annual Report available now

AROA is pleased to advise it’s FY23 Annual Report is available now. To find out…

June 15, 2023
Scott Sherriff appointed as inaugural Chief Operating Officer

Aroa Biosurgery (AROA, ASX: ARX) is delighted to announce the appointment of seasoned executive Scott…

More from AROA

May 31, 2023
FY23 Full Year Results and Outlook for FY24

AROA is pleased to release its audited full year results for the period ended 31…

Read More
April 27, 2023
March 2023 – Quarterly Results

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results…

Read More
April 12, 2023
AROA SECURES FIRST FDA CLEARANCE FOR ENIVO™ SYSTEM.

Highlights • AROA has received U.S. FDA 510K clearance for its Enivo™ pump and catheter,•…

Read More
March 31, 2023
Dr Brian Ward inducted into Biotech New Zealand Hall of fame.

The inaugural Biotech NZ Life Sciences Summit was held in Wellington on March 22 and…

Read More
March 14, 2023
AROA AWARDED REGENERATIVE SKIN GRAFTING PRODUCTS AGREEMENT WITH PREMIER, INC.

Highlights AROA has been awarded a group purchasing agreement for its Myriad™ and Symphony™ products,…

Read More
February 20, 2023
NPWT and Collagen matrices study

First of its kind study shows promising results for combined use of negative pressure wound…

Read More
January 31, 2023
December 2022 Quarterly Results

Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update…

Read More
November 29, 2022
Aroa Biosurgery Half Yearly Report H1 FY23

Today Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23….

Read More
September 13, 2022
Dr Catherine Mohr to join AROA Board of directors

Aroa Biosurgery, (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor,…

Read More
August 9, 2022
2022 AGM Update

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘AROA’ or the ‘Company’)advises that following recent…

Read More
November 25, 2021
Aroa Biosurgery Half Yearly Report H1 FY23

Today Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23….

Read More
August 10, 2021
Real-World Data shows Aroa Biosurgery’s Endoform™ Natural achieves significantly improved wound ...

Highlights A retrospective analysis of real-world data published in the ‘International Wound Journal’ compared the…

Read More
August 4, 2021
Aroa Biosurgery’s Myriad Matrix receives validation for reconstruction of tissues affected by Pilo...

Highlights• AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in…

Read More
July 16, 2021
Aroa Biosurgery June 2021 4C – Commentary

HIGHLIGHTS US medical procedure numbers continue to reflect a positive trend supporting improved sales momentum….

Read More
June 21, 2021
Aroa Biosurgery releases FY2021 Annual Report

Aroa Biosurgery is pleased to release its first Annual Report since successfully completing its IPO…

Read More
April 28, 2021
Aroa Biosurgery March 2021 4C – Commentary

HIGHLIGHTS H2 FY21 product revenues (unaudited) grew 16% on H2FY20 to $13.8m on a constant…

Read More
April 6, 2021
Aroa Biosurgery secures FDA clearance for new product, Myriad Morcells™, offering highly conformab...

HIGHLIGHTS U.S. FDA 510(k) clearance received for a new Aroa Biosurgery product named Myriad Morcells™,…

Read More
February 16, 2021
Pilot study indicated benefits of Aroa Biosurgery’s Myriad™ in surgical reconstruction of chroni...

HIGHLIGHTS Aroa’s Myriad™ may be used successfully under a tissue flap to reduce surgical complications…

Read More
February 2, 2021
Aroa Biosurgery to further expand fully dedicated sales team for key U.S. market

HIGHLIGHTS Aroa to expand on its own direct field sales presence in the United States…

Read More
December 16, 2020
New study shows Aroa Biosurgery’s Myriad™ efficacy in healing exposed vital body structures

HIGHLIGHTS Aroa’s Myriad™ is further validated in a clinical study and peer-reviewed publication – Journal…

Read More
December 9, 2020
Indian regulatory approval received for three Aroa products

HIGHLIGHTS The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), approves…

Read More
November 12, 2020
Aroa Biosurgery’s Myriad™ shown to be effective in surgical treatment of Hidradenitis Suppurativ...

HIGHLIGHTS Further validation for Aroa’s MyriadTM from clinical study and peer-reviewed publication in Journal of…

Read More
August 19, 2020
Aroa Biosurgery’s Endoform® platform shown to attract stem cells

HIGHLIGHTS Further validation gained for Aroa’s proprietary Endoform® platform with peer-reviewed publication in PLOS ONE….

Read More
July 30, 2020
European approval received for Myriad™

HIGHLIGHTS CE Mark to allow commercialization of Aroa’s Myriad™ product in the EU Myriad™ is…

Read More
July 30, 2020
Aroa Biosurgery secures FDA Clearance for Symphony™

HIGHLIGHTS U.S. FDA clearance received for a new Aroa Biosurgery product Symphony™, designed to support…

Read More
June 23, 2020
Aroa Biosurgery to list on the ASX in $225m IPO

Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the…

Read More
March 31, 2020
Aroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the Uni...

San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians…

Read More
March 25, 2020
COVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ pr...

Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture…

Read More
February 21, 2020
Aroa Biosurgery expands options for soft tissue repair with launch of Myriad™

Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has launched Myriad™, a…

Read More
February 16, 2020
Aroa Biosurgery launches large format Endoform® to treat larger, more complex wounds

Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a…

Read More
December 13, 2019
Aroa Biosurgery appoints experienced Australian-based director

Auckland, NZ. Aroa Biosurgery Limited (Aroa), a New Zealand-headquartered, privately held soft-tissue repair company has…

Read More
October 17, 2019
Aroa Biosurgery appoints new Vice President, Commercial

Auckland, NZ. Aroa Biosurgery a New Zealand-headquartered, emerging global leader for tissue regeneration products used…

Read More
October 3, 2019
Aroa Biosurgery grows into additional markets with positive outcomes from Canadian clinical study

Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive…

Read More
September 12, 2019
Aroa Biosurgery posts maiden profit as it expands sales presence in U.S. and global markets

Auckland, NZ. Aroa Biosurgery has posted a modest profit for the FY18/19 year, a first…

Read More
January 21, 2019
TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair ...

1,000 cm2 device now commercially available in the U.S. rounds out portfolio of surgical mesh…

Read More
June 26, 2018
TELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral H...

Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC….

Read More
June 11, 2018
TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe

MALVERN, Pa., May 31, 2018 /PRNewswire/ — TELA Bio®, Inc., a surgical reconstruction company leading…

Read More
June 4, 2018
Aroa Biosurgery and Hydrofera Team up in US

MANCHESTER, Conn. & AUCKLAND, New Zealand–(BUSINESS WIRE)–New Zealand biomedical company Aroa Biosurgery and United States…

Read More
November 27, 2017
FDA Clearance for Endoform® Silver Dermal Template

Aroa Biosurgery has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for the…

Read More
October 31, 2017
Big investment in Aroa Biosurgery‘s Commercial Partner

New Zealand biomedical company Aroa Biosurgery faces accelerating growth after a significant investment of up…

Read More
May 17, 2017
EC Certification for Endoform® Dermal Template

Aroa Biosurgery has received EC Certification for its Endoform® Dermal Template (“EDT”), which allows the…

Read More
March 12, 2017
510(k) Clearance Received for Endoform® Plastics and Reconstructive Matrix

Aroa Biosurgery has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for the…

Read More
March 12, 2017
Aroa Biosurgery successfully raises additional capital to fund growth

Aroa Biosurgery has successfully raised additional capital from new and existing investors from the USA,…

Read More
March 12, 2017
Launch of Ovitex Reinforced Bioscaffolds

Aroa Biosurgery’s partner, TelaBio, Inc. announced today, the commercial launch of the Ovitex™ Reinforced Bioscaffolds…

Read More
October 12, 2015
Aroa Biosurgery wins NZBIO top award

NZBIO delegates pick Aroa Biosurgery for top honour Aroa Biosurgery has been named as New…

Read More
June 19, 2015
Aroa Biosurgery poised for global growth

Mesynthes renamed for new strategic direction Auckland June 22, 2015: Mesynthes Ltd, a privately held…

Read More
February 27, 2015
Aroa Corporate Update

Aroa has changed a lot over the last seven years. We started as a company…

Read More